



What is claimed is:

1. A method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II):



Formula (I)



Formula (II)

wherein

phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,

10


$R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are independently selected from the group consisting of hydrogen and  $C_1$ - $C_4$  alkyl; wherein  $C_1$ - $C_4$  alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, amino, nitro and cyano).

15


2. The method of claim 1 wherein X is chlorine.
3. The method of claim 1 wherein X is substituted at the ortho position of the phenyl ring.
4. The method of claim 1 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are selected from hydrogen.

20

5. A method for preventing or treating anxiety disorders comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer selected from the group consisting of Formula (I) and Formula (II) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates:



Formula (I)



Formula (II)

wherein

phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,


$R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are independently selected from the group consisting of hydrogen and  $C_1$ - $C_4$  alkyl; wherein  $C_1$ - $C_4$  alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, amino, nitro and cyano).

6. The method of claim 5 wherein X is chlorine.
7. The method of claim 5 wherein X is substituted at the ortho position of the phenyl ring.
8. The method of claim 5 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are selected from hydrogen.

9. The method of claim 5 wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 90% or greater.

10. The method of claim 5 wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 98% or greater.

11. The method of claim 5 wherein the enantiomer selected from the group consisting of Formula (I) and Formula (II) is an enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa):



wherein


phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,

$R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are independently selected from the group consisting of hydrogen and  $C_1$ - $C_4$  alkyl; wherein  $C_1$ - $C_4$  alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, amino, nitro and cyano).


12. The method of claim 11 wherein X is chlorine.

13. The method of claim 11 wherein X is substituted at the ortho position of the phenyl ring.

14. The method of claim 11 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are selected from hydrogen.
- 5 15. The method of claim 11 wherein one enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates to the extent of about 90% or greater.
- 10 16. The method of claim 11 wherein one enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates to the extent of about 98% or greater.
- 15 17. The method of claim 5 wherein the enantiomer selected from the group consisting of Formula (I) and Formula (II) is an enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb):



Formula (Ib)



Formula (IIb)

18. The method of claim 17 wherein one enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates to the extent of about 90% or greater.
- 20 19. The method of claim 17 wherein one enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates to the extent of about 98% or greater.

Sub A1

- 5 20. The method as in claims 1 or 5 wherein anxiety disorders are selected from generalized anxiety disorder, panic disorders, impulse control disorders, phobic disorders, posttraumatic stress disorder, dissociative states (selected from amnesia, somnambulism, dissociative identity disorder or depersonalization), presurgical anxiety states, postsurgical anxiety states or other medical or psychiatric induced anxiety conditions (selected from anxiety resulting from traumatic brain injury, chronic pain disorders or other chronic disease conditions).
- 10 21. The method of claim 20 wherein anxiety disorders are selected from generalized anxiety disorder, panic disorders, impulse control disorders, phobic disorders or posttraumatic stress disorder.
- 15 22. The method of claim 21 wherein the anxiety disorder is posttraumatic stress disorder.
- 20 23. The method of claim 21 wherein panic disorders are selected from panic disorders with agoraphobia, panic disorders without agoraphobia, anticipatory anxiety, recurrent sleep panic attacks, distressing symptoms (selected from dyspnea, tachycardia, palpitations, headaches, dizziness, paresthesias, choking, smothering feeling, nausea or bloating) or feelings of impending doom; wherein impulse control disorders are selected from obsessive-compulsive disorder, bulimia, episodic
- 25 dyscontrol, trichotillomania, compulsive gambling and kleptomania; and, wherein phobic disorders are selected from social phobia, global social phobia, specific social phobia, simple phobia, agoraphobia, apiphobia, tropophobia, astraphobia, triskaidekaphobia, blennophobia, thalassophobia, claustrophobia, spheksophobia, cynophobia,
- 30 sciophobia, decidophobia, eletrophobia, scholionophobia, eremophobia, pyrophobia, gamophobia, pnigerophobia, ophidiophobia, odynophobia, nyctophobia, ochlophobia, musophobia, keraunophobia, katagelophobia, kakorraphiophobia, hydrophobia, gynophobia,

gatophobia, gephyrophobia, acrophobia or amathophobia.

24. The method of claim 23 wherein the impulse control disorder is obsessive-compulsive disorder.

5

25. The method as in claims 1 or 5 wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.

10081713.022102